Reviewed by Sarah Alter, Ph.D. — Scientific Affairs, OrganaBio. 15 years of immunology research spanning autoimmunity, cancer, and infectious disease. University of Miami Miller School of Medicine. Registered Patent Agent.
What Is B Cell Isolation From PBMCs?
B cell isolation from PBMCs is the enrichment of CD19+ B lymphocytes from peripheral blood mononuclear cells for antibody discovery, vaccine response research, autoimmune disease modeling, and B cell biology studies. B cells represent 5–15% of circulating PBMCs. They are the precursors to antibody-secreting plasma cells and play central roles in autoimmune diseases where autoreactive B cells and pathogenic autoantibody production drive tissue damage.
B Cell Subsets: What You Are Isolating and Why It Matters
The bulk CD19+ population from peripheral blood contains multiple B cell developmental stages with distinct functions. Depending on the research question, different subsets are relevant:
| Subset | Key markers | Function |
|---|---|---|
| Naive B cells | CD19+CD27−IgD+ | Antigen-inexperienced; antibody libraries |
| Memory B cells | CD19+CD27+IgD− | Affinity-matured; vaccine response, autoimmune drivers |
| Plasmablasts | CD19+CD38hiCD27hi | Antibody secretion; transient after antigen challenge |
| Transitional B cells | CD19+CD24hiCD38hi | Regulatory function; IL-10 secretion (Bregs) |
| Age-associated B cells | CD19+CD11c+T-bet+ | Expanded in SLE, RA, aging; autoreactive tendency |
In autoimmune disease, B cell subset distribution shifts substantially. SLE donors show expanded age-associated B cells (ABCs, CD11c+T-bet+) and plasmablasts, with anti-dsDNA antibody-secreting cells detectable directly from peripheral blood. Sjögren’s donors show expanded CXCR5+ memory B cells from ectopic germinal center activity. For any autoimmune research where B cell phenotype is the relevant variable, disease-state donors provide the appropriate biology.
B Cell Isolation Protocol From Leukopak PBMCs
Negative selection is preferred for most B cell applications to preserve CD19 surface expression and avoid crosslinking artifacts from direct CD19 bead labeling.
Negative Selection Protocol
Step 1: Thaw cryopreserved PBMCs at 37°C, rest 1–2 hours in RPMI + 10% human AB serum at 37°C/5% CO₂. Dead cell removal recommended for disease-state donors (viability <85% post-thaw).
Step 2: Apply a B cell negative selection kit. These kits deplete T cells (CD3), NK cells (CD56), monocytes (CD14), and dendritic cells (CD11c, CD123). The unlabeled fraction is CD19+ B cells.
Step 3: Collect the negative fraction. Target purity: ≥90% CD19+ by flow cytometry. Typical yield: 75–85% of input B cells recovered.
Step 4: Validation flow panel: CD19, CD27, IgD, CD38, CD24 for subset distribution. For SLE and Sjögren’s donors, add CD11c and T-bet for ABC identification, and CXCR5 for germinal-center-associated memory B cells.
CD19+ Positive Selection (High-Purity Applications)
For applications requiring ≥98% B cell purity (single-cell sequencing, direct antibody gene amplification, ELISPOT assays), CD19 positive selection with anti-CD19 MicroBeads is appropriate. Note: CD19 crosslinking by beads can activate B cells and upregulate CD69 and CD86. For experiments sensitive to B cell activation state at isolation, negative selection is preferred even at lower purity.
Disease-State B Cells: Applications in Autoimmunity and Antibody Research
Autoantibody Discovery
Memory B cells and plasmablasts from autoimmune donors carry somatically hypermutated variable region genes encoding disease-relevant autoantibodies. Direct isolation and immortalization (EBV transformation or single-cell BCR cloning) from autoimmune donors is the most direct path to naturally occurring autoantibody sequences. Healthy donor B cells cannot provide this. OrganaBio’s SLE, pemphigus vulgaris, myasthenia gravis, Graves’ disease, and NMOSD donors are particularly relevant for programs targeting disease-specific autoantibodies (anti-dsDNA, anti-Dsg3, anti-AChR/MuSK, anti-TSH-R, anti-AQP4).
BTK and B Cell Pathway Inhibitor Research
BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) target B cell receptor signaling and are approved for B cell malignancies and are in trials for autoimmune disease. Disease-state B cells with active BCR signaling from autoimmune donors provide the relevant target population for BTK pathway research. Pemphigus vulgaris, in particular, involves IgG4 anti-Dsg3 B cells with active BTK-dependent BCR signaling — disease-state donors from OrganaBio provide these cells for drug testing in a biologically relevant context.
Vaccine Response and Memory B Cell Profiling
Post-vaccination memory B cells represent a specific antigen-specific memory population detectable in peripheral blood 4–8 weeks after immunization. Donors with documented vaccination history (COVID-19, influenza, hepatitis B) enable antigen-specific memory B cell studies without in vitro immunization artifacts. OrganaBio documents vaccination history in donor records — contact the scientific team to discuss antigen-specific donor selection.
B Cell Isolation Considerations for Disease-State Donors
Three variables unique to disease-state B cell work that differ from healthy donor protocols:
Higher plasmablast frequency: Active SLE and Sjögren’s donors may have elevated circulating plasmablasts (CD19loCD38hiCD27hi) that have partially downregulated CD19 surface expression. Standard CD19-based isolation will recover fewer plasmablasts than a CD38+CD27+ combination isolation. Plan for this if plasmablast frequency in the isolated population is relevant.
Elevated ABC frequency: Age-associated B cells (CD11c+T-bet+) express CD19 and will be recovered in the bulk isolation. If ABC enrichment or depletion is needed for the experiment, additional flow sorting steps are required post-magnetic isolation.
Immunosuppressive medication effects: Disease-state donors on B cell-depleting therapies (rituximab) will have substantially lower CD19+ counts. OrganaBio documents medication history on all disease-state donor records — donors on active B cell depletion are identifiable before ordering.
Contact the scientific team to discuss disease-state donor selection for B cell isolation, autoantibody discovery, or subset-specific applications.
